Octreotide therapy in asparaginase-associated pancreatitis in childhood acute lymphoblastic leukemia.
Little is known about octreotide therapy in asparaginase-associated pancreatitis (AAP) in children. Of the 59 children with acute lymphoblastic leukemia (ALL) receiving E. coli L-asparaginase, 5 patients (8.5%) developed AAP. Octreotide was administered to four patients. Clinical and laboratory improvement were evident after octreotide therapy. There were no deaths and no severe adverse side effects were noted. No pseudocysts were detected; however, two of the four patients developed diabetes. One child without octreotide treatment developed chronic pancreatitis and pseudocyst. We conclude that octreotide therapy appears to be safe and potentially beneficial in the management of AAP in children.
Wu
Shu-Fen
SF
Division of Pediatric Gastroenterology, China Medical University Hospital, Taichung, Taiwan.
Chen
An-Chyi
AC
Peng
Ching-Tien
CT
Wu
Kang-Hsi
KH
D000293:Adolescent; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001215:Asparaginase / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D015282:Octreotide / Q000627:therapeutic use*; D010195:Pancreatitis / Q000139:chemically induced / Q000188:drug therapy*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D005765:Gastrointestinal Agents; D001215:Asparaginase; D015282:Octreotide